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Abstract:  
 
Diastolic heart failure (DHF) is estimated to occur in 40% to 50% of patients with heart failure. 
Evidence suggests that DHF is primarily a cardiogeriatric syndrome that increases from 
approximately 1% at age 50 years to 10% or more at 80 years. DHF is also more likely to occur 
in older women who are hypertensive or diabetic. Although survival is better in patients with 
DHF compared with systolic heart failure, mortality rates for patients with DHF are four times 
higher than those for healthy, community-dwelling older adults. The increase in DHF is 
anticipated to continue during the next several decades largely because of the aging of the 
population; increase in risk factors associated with hypertension, diabetes, and obesity; and 
ongoing technologic advances in the treatment of cardiovascular disease. Few clinical trials have 
evaluated therapy in this population, so evidence about the effectiveness of treatment strategies 
for DHF is limited. Future research should target novel interventions that specifically target 
patients with DHF who are typically older and female, and experience exertional intolerance and 
have a considerably reduced quality of life. 
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Article:  
 
Approximately 550,000 individuals in the United States are diagnosed with heart failure (HF) 
annually, and this number is anticipated to increase to 1.5 million by 2040, largely because of the 
aging of the population, positive lifestyle modifications, and technologic advances in the 
treatment of coronary artery disease.1 HF is the leading reason for hospital admissions and death 
among older adults and is the most expensive Medicare expenditure, with costs estimated to be 
between 30 and 40 billion dollars annually.2-8Evidence indicates that diastolic heart failure 
(DHF) and systolic heart failure (SHF) are equally distributed in the population, and that they 
differ in pathologic mechanisms and in the gender and age of those affected.9-13 However, 
despite the potential economic and clinical implications of DHF, few clinical trial data are 
available and treatment continues to remain largely empirical.14 
 
Table I. Differences and similarities between systolic and diastolic heart failure 
 Systolic heart failure present Diastolic heart failure present 
Signs and symptoms 
  
BNP ↑↑ ↑ 
Exercise testing 
 Duration ↓ ↓ 
 Systolic BP ↑ ↑↑ 
 Pulse pressure ↑ ↑↑ 
 VO2 ↓↓ ↓ 
LV remodeling 
 End-diastolic volume ↑↑ N 
 End-systolic volume ↑↑ ↓ 
 Myocardial mass ↑ (eccentric LVH) ↑ (concentric LVH) 
 Relative wall thickness ↓ ↑↑ 
 Cardiomyocyte ↑ length ↑ diameter 
 EC matrix (collagen) ↓ ↑↑ 
LV systolic function 
 Ejection fraction ↓↓ N-↑ 
 Stroke volume N-↓ N-↓ 
 Myocardial contractility ↓↓ ↓ 
LV diastolic function 
 Chamber stiffness N-↓ ↑↑ 
 Myocardial stiffness N-↑ ↑ 
 Relaxation time-constant ↑ ↑ 
 Filling dynamics abnormal abnormal 
 End-diastolic pressure ↑↑ ↑↑ 
 Preload reserve exhausted limited 
Morbidity ↑↑ ↑↑ 
Survival ↓↓ ↓ 
BNP, Brain natriuretic peptide; BP, blood pressure; VO2, oxygen consumption; LV, left 
ventricular; LVH, left ventricular hypertrophy; EC, extracellular. 
Reprinted with permission from Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and 
diastolic heart failure. Annu Rev Med 2004;55:373-94. 
 
HF, whether systolic or diastolic, is a complex syndrome characterized by dyspnea and fatigue 
secondary to structural and functional changes in the heart resulting from a variety of conditions 
that occur in conjunction with neurohormonal and cytokine activation. Diastolic dysfunction is 
caused by an abnormality of the mechanical properties (distensibility, filling, and relaxation) of 
the left ventricle (LV). Patients with diastolic dysfunction may experience HF symptoms, be 
asymptomatic, or have a normal or even low left ventricular ejection fraction (LVEF) when also 
associated with systolic impairment. Diastolic dysfunction is caused by factors that are intrinsic 
to the myocardium, such as those affecting the cardiomyocytes, extracellular matrix, or vascular 
system, which has both similarities and differences to systolic dysfunction as shown in Table I.15-
21 
 
Patients with DHF exhibit classic HF symptoms (eg, dyspnea, fatigue, and evidence of 
pulmonary congestion on chest radiograph). In the majority of patients, the primary reason for 
DHF is diastolic dysfunction. However, systolic function is normal as evidenced by an LVEF of 
50% or more.8,16-20,22 Brain natriuretic peptide (BNP) has improved the ability to diagnose DHF 
and is useful for excluding other conditions, but does not differentiate DHF from SHF.23,24 
 
Epidemiology 
 
The Cardiovascular Health Study (CHS)9,10 was the first large epidemiologic study (N = 4842) to 
examine cardiovascular disease risk in the elderly. HF was present in 425 subjects (8.8%) of the 
sample, whose mean age was 77 ± 5 years. This was most notable among women, in whom HF 
increased from 6.6% at age 65 to 69 years to 14% at age greater than 85 years. More than half 
(55%) of the women in the CHS exhibited a normal LVEF, and LVEF was only mildly reduced 
in 80% of the women.10 DHF was more common in women than men (67% vs 42%; P < .001), 
which is consistent with findings from the Framingham study5,7,25,26 and others.13,27-29 
 
More recent findings from the Candesartan in Heart Failure-Assessment of Reduction in 
Mortality and Morbidity (CHARM) trial,30 consisting of three component studies comparing 
placebo with candesartan, support earlier epidemiologic findings of increased DHF among 
women. The proportion of women in CHARM-Preserved (LVEF ≥ 40%)31 was 40%. This 
number was higher than the 32% of women reported in the CHARM-Alternative arm of the 
study (LVEF ≤ 40%, intolerant to angiotensin-converting enzyme inhibitors [ACEIs], and not 
previously taking angiotensin receptor blockers [ARBs])32 and considerably more than the 21% 
of women who were enrolled in the CHARM-Added component (LVEF ≤ 40%, ACEIs, or 
placebo in addition to candesartan).33 Patients in the CHARM-Preserved study were more often 
hypertensive than patients in the CHS or Framingham studies (64% vs 50% and 48%, 
respectively). Compared with previous trials, the CHARM-Preserved subjects were older, more 
likely to be women, more likely to have a history of hypertension, less likely to report a previous 
myocardial infarction, and more likely to have New York Heart Association (NYHA) class 
II.31 Preliminary findings from the Irbesartan in Heart Failure with Preserved EF (I-Preserve 
trial),34 the largest trial to evaluate an ARB in patients with DHF (N = 4100), revealed that 60% 
were women, hypertension was the primary cause, and most were aged more than 70 years. 
 
Prognosis and Hospitalizations 
 
Among community samples, the mortality rates for patients with SHF are 10% to 15% annually, 
higher than the 4% to 8% observed in patients with DHF.2,10 However, the death rate among 
patients with DHF is approximately four to five times higher compared with adults with normal 
diastolic function, indicating its serious impact.10 Short-term survival and hospital readmission 
rates are more favorable in younger patients with DHF (<65 years) than patients with SHF but 
are similar at age 75 years or more.2,3,35-37 Evidence also suggests that elderly patients with DHF 
are less likely to receive optimal treatment with ACEIs and beta-blockers, which may contribute 
to the poor outcomes in this age group.2,38 
 
The cause of DHF seems to play an important role in prognosis and mortality. Although 
coronary artery disease is common in both systolic and diastolic HF, an ischemic cause is 
associated with higher mortality rates in DHF.39 In addition, if diastolic dysfunction is present in 
the early stages of an acute myocardial infarction, HF and death are more probable.3,4,19 The 
number of hospitalization readmissions related to nonischemic causes of DHF, however, is not 
significantly different than SHF. African Americans with DHF may be particularly susceptible to 
poor clinical outcomes because diabetes, hypertension, and obesity, all known to cause and 
exacerbate DHF, are more prevalent, severe, and poorly controlled.40 The influence of 
socioeconomic disparities and health care access on the incidence and prevalence of in DHF is 
warranted among medically underserved populations who are more likely to have poorly 
controlled hypertension, diabetes, and higher rates of obesity.41 
 
Pathophysiology of Diastolic Heart Failure 
 
Although much less is known about DHF than SHF, the pathogenesis in most cases seems to be 
associated with LV diastolic impairment and is the focus of this review. However, conditions 
such as right-sided HF, lung disease, and pericardial and valvular heart diseases are also 
acknowledged to contribute to the pathologic changes associated with DHF.17-20 
 
Diastolic dysfunction is associated with delayed LV relaxation, reduced distensibility (increased 
diastolic pressure with no change in volume), and increased chamber stiffness (increased slope of 
the diastolic pressure/volume relationship).17 In contrast with those with SHF, patients with DHF 
show an inability to increase stroke volume via the Frank-Starling mechanism, even with severe 
elevation in LV filling pressures. A relatively small increase in blood volume can result in a 
substantial increase diastolic pressure and lead to pulmonary congestion and edema as illustrated 
in Fig 1.17,19,20 Moreover, atrial fibrillation is particularly detrimental in patients with DHF, who 
depend on the atrial “kick” or contraction to maintain both end-diastolic and stroke volumes.17-20 
 
FIGURE 1 IS OMITTED FROM THIS FORMATTED DOCUMENT 
 
Fig 1. Pressure-volume loops contrasting isolated diastolic heart failure (A) with systolic heart 
failure (B) and combined systolic and diastolic heart failure (C). A normal patient (solid line) is 
compared with a patient with heart failure before (dashed line) and after (dotted line) treatment. 
HF indicates heart failure. Reprinted with permission from: Zile MR, Brutsaert DL. New 
concepts in diastolic dysfunction and diastolic heart failure: Part I. Circulation 
2002;105(11):1387-1398. 
 
Cardiac remodeling occurs in both diastolic and systolic HF, but there are structural differences. 
Patients with DHF develop concentric hypertrophy, which includes a normal or reduced cardiac 
cavity size, an increased wall thickness, and a high mass/cavity ratio. The end-systolic and 
diastolic volumes are normal in most patients with DHF, and LVEF is normal or elevated. In 
contrast, patients with SHF have increased cavity size (eccentric remodeling), decreased or 
unchanged wall thickness, normal or reduced mass/cavity ratio, elevated systolic and diastolic 
volumes, and lower LVEF. 
 
LV wall stress, neurohormonal and cytokine activation, and abnormal calcium regulation occur 
in both systolic and diastolic HF. However, collagen metabolism seems to differ in SHF and 
DHF and may explain in part the disparate structural changes associated with remodeling. With 
DHF progression, there is evidence of greater fibrillar collagen, collagen cross-links, and 
fibrosis. In addition, patients with DHF exhibit a reduction in matrix metalloproteinases and 
increase in tissue inhibitors of metalloproteinases. These changes are associated with loss of the 
normal supporting interstitial structure. Other evidence of abnormal collagen metabolism 
includes an increase in the ratio of titin isoforms N2BA/N2B. In addition, myocyte diameter is 
reportedly higher among patients with DHF compared with patients with SHF. The processes 
related to myocyte hypertrophy, cytoskeletal alterations, and fibrosis are not fully understood. 
However, because reversing or slowing remodeling is an important therapeutic target, changing 
the underlying collagen metabolism and regulation may be an important therapeutic goal for 
DHF in the future.17-20 
 
Aging 
 
Because DHF primarily occurs in older adults, age-related physiologic and pathologic changes 
likely contribute to the development of DHF.42 Hemodynamic changes include a decline in 
maximal heart rate, cardiac output, and maximal oxygen consumption (peak VO2). Stroke 
volume stays relatively unchanged or may decrease, whereas systemic vascular resistance 
increases, which elevates blood pressure and afterload.2,5,17,21,42 With aging there is also greater 
LV stiffness, reduced LV compliance, increased LV wall thickness, reduction in myocardial and 
vascular responsiveness to beta-adrenergic stimulation, and lower mitochondrial response to 
higher demand for adenosine triphosphate production.42 
 
Hypertension 
 
Evidence suggests hypertension plays a central role in the development of diastolic dysfunction 
and DHF. Animal evidence supports that diastolic dysfunction occurs early in hypertension and 
that LV relaxation is responsive to increased afterload. Further, epidemiologic studies 
consistently indicate hypertension increases the risk for DHF up to threefold compared with 
those who are normotensive.7,9 For example, the Framingham study reported hypertension 
preceded DHF in 91% of cases, and hypertension was present in equal numbers among CHS 
participants.43 In studies using Doppler echocardiography, up to 20% of persons experiencing 
borderline or mild hypertension demonstrated impaired diastolic filling.44-46 These findings 
indicate echocardiography screening may be advantageous for those at high risk for hypertension 
or who have prehypertension to determine diastolic dysfunction at earlier stages and perhaps 
prevent progression to DHF. 
 
Hypertension increases LV afterload, which results in delayed relaxation time, elevated LV 
filling pressure, and reduced end-diastolic volume.16,17,44,47,48 These pathologic changes are 
associated with abnormal myocyte stretching, sympathetic nervous system activation, and 
progressive neurohormonal and cytokine release.49 These changes are associated with 
myocardial apoptosis and ventricular remodeling, which contributes to increased LV mass and 
further loss of compliance.50 The role of genetic predisposition is not well understood but 
suggests that there may be substantial heritability for hypertension and increased LV mass 
associated with DHF and is an important area for future study. 
 
Obesity 
 
Obesity, defined as a body mass index >30 kg/m2, is a growing epidemic; increasing evidence 
suggests it may play an important role in the development of diastolic 
dysfunction.51 Echocardiography provides the opportunity to evaluate and compare cardiac 
structure and changes among varying degrees of obesity and normal weight, and between 
symptomatic and asymptomatic patients.52 For example, Powell and colleagues51examined the 
relationship among body mass index, LV structure, and systolic and diastolic function in 4281 
patients who did not have greater than 50% coronary stenosis via coronary angiography. 
Echocardiography measurements determined that a higher body mass index was associated with 
greater LV mass (r = .18; P < .001), LV wall thickness (r = .17; P < .001), and LV end-diastolic 
diameter (r = .07; P < .001). These findings are consistent with other reports supporting obesity 
as a contributing factor for ventricular remodeling, impaired LV relaxation, and higher LV filling 
pressures, which lead to diastolic dysfunction and DHF. Gender differences in obesity may also 
influence the development of DHF because overweight and obese women experience DHF at 
higher numbers compared with overweight and obese men.53 
 
Diabetes 
 
Several studies have shown that HF is two to five times more likely to occur among diabetic 
persons than nondiabetic persons.54 Evidence suggests that diastolic dysfunction may be one of 
the first signs of diabetic cardiomyopathy. For example, one study showed among 86 patients 
(43% women) with diabetes that more than 40% had diastolic dysfunction, 26% had impaired 
relaxation, and 17% had pseudonormalization (defined below) on Doppler 
echocardiography.55 These findings are important because the patients were young (mean age 43 
years) and normotensive, and had well-controlled diabetes (mean hemoglobin A1c, 6.5 g/dL). 
These findings are supported by the Strong Heart Study (N = 2411 Native Americans) that 
reported impaired LV relaxation among diabetic persons. In addition, those with diabetes and 
hypertension had even greater impairment in LV relaxation when compared with those with 
diabetes alone.56 As suggested previously, echocardiography screening may be an important 
diagnostic strategy for identifying early diastolic impairment before it progresses to DHF. 
 
Poor glycemic control and an elevated hemoglobin A1c may be associated with impaired LV 
relaxation. Among 49,000 diabetic persons enrolled in a registry, poor glycemic control 
increased the risk for HF. For every 1% increase in hemoglobin A1c, the incidence of HF risk 
increased by 8%.51 In another study, microalbuminemia was identified as a risk factor for the 
development of diastolic dysfunction. Findings from the Strong Heart Study showed a direct 
correlation between increasing urinary albumin excreted and LV diastolic dysfunction.56 An 
altered myocardial glucose and increased fatty acid metabolism related to diabetes may be 
associated with changes in myocardial structure. These changes include myocyte hypertrophy, 
increased collagen, interstitial fibrosis, and intramyocardial microangiopathy, all of which 
contribute to the development of diastolic dysfunction and DHF.56 Because diabetes is an 
important risk factor for DHF, management of diabetes mellitus should incorporate prevention 
and treatment of DHF, especially among those with comorbid hypertension. 
 
Multiple comorbidities 
 
Because patients with DHF are often older, the presence and management of multiple 
comorbidities are often a reality in the clinical setting. A recent study of Medicare beneficiaries 
showed that patients hospitalized with HF frequently have two to six comorbidities, whereas a 
substantial number have seven or more coexisting illnesses.57,58It is important that health care 
providers are aware that polypharmacy is common in many elderly patients with DHF and may 
have potential deleterious consequences. For example, arthritis is a common condition in many 
older women with DHF, and many are prescribed nonsteroidal anti-inflammatory medications 
for chronic pain relief. These agents are known to promote fluid retention, elevate blood 
pressure, interfere with the action of ACEIs, and possibly worsen renal function.8,58 Poor renal 
function is increasingly associated with poor clinical outcomes in HF, both systolic and diastolic. 
 
Clinical manifestations 
 
The clinical signs and symptoms of DHF include exertional dyspnea and fatigue, orthopnea, 
paroxysmal nocturnal dyspnea, lower-extremity edema, and exercise intolerance. In addition, 
pulmonary congestion, peripheral edema, and abdominal bloating may occur as the result of 
hepatic congestion. Because many patients with DHF are older, it is important to consider 
atypical symptoms that may occur, including lethargy, malaise, loss of appetite, confusion, 
irritability, fatigue, and reduced physical activity level.2,8,59,60 
 
Despite having a normal LVEF, patients with DHF often experience considerable exertional 
intolerance.16,20,61,62 This is consistent with studies that show little relation between LVEF and 
level of exertional intolerance. Patients with SHF and low LVEF may have equal or better 
exercise tolerance than patients with DHF who have a high or normal LVEF.61-63Several factors 
explain the exertional intolerance observed in patients with DHF. First, dyspnea results from 
reduced lung compliance secondary to increased LV diastolic and pulmonary venous pressure. 
Second, a lower stroke volume and cardiac output occurs despite a normal LVEF. Third, failure 
of the Frank Starling mechanism limits preload reserve and prevents cardiac output from 
increasing proportionately to the increased demands of exercise.20 Finally, because many patients 
with DHF are older and often sedentary, physical deconditioning is common, which hastens the 
peripheral musculoskeletal alterations and leads to greater symptom severity and functional 
status decline.63 
 
Clinical Evaluation 
 
Initially, clinical evaluation of DHF includes a medical history, physical examination, chest 
radiograph, serum BNP, and electrocardiogram. Symptom similarity with other medical 
conditions, such as asthma and chronic obstructive pulmonary disease, has increased serum BNP 
use in clinical settings. A detailed review of cardiac symptoms including ischemic heart disease, 
such as chest pain, history of angina, myocardial infarction, arrhythmias, especially 
tachyarrhythmias, or valvular disease, should be evaluated. Pulmonary symptoms, such as 
dyspnea on exertion, paroxysmal nocturnal dyspnea, and orthopnea, which often occur in 
pulmonary or valvular disease, may mimic or cloud the ability to diagnose DHF. Less common 
conditions contributing to DHF that should be incorporated routinely in the history are thyroid 
diseases and anemia.2,8,17,20 
 
A number of physical signs accompany DHF and include elevated jugular venous pressure, 
hepatojugular reflex, and an S4 or S3 gallop. However, an S4 (atrial gallop) occurs with greater 
frequency in patients with DHF because it reflects reduced compliance of the LV or left 
ventricular hypertrophy (LVH). Chest radiograph remains an important preliminary diagnostic 
test and may reveal the presence of pulmonary congestion or pleural effusion. A baseline 
electrocardiogram may suggest findings consistent with LVH. BNP levels correlate well with LV 
end-diastolic pressure, pulmonary artery wedge pressures, LVH, and systolic/diastolic 
dysfunction, but they do not differentiate the type of HF. Higher BNP is closely correlated with 
NYHA class and mortality, with higher levels associated with poorer clinical outcomes.8,59,60 
 
Diagnostic measures 
 
A precise diagnosis of diastolic dysfunction is often difficult and requires invasive techniques to 
determine LV volume, relaxation, and compliance properties. An abnormal upward shift of the 
end-diastolic pressure-volume curve obtained during radionuclide ventriculography is 
characteristic of diastolic impairment. This includes increased LV end-diastolic pressure with 
normal LV volume and systolic function. Concurrent pressure, volume, and geometry 
measurements can be taken throughout the cardiac cycle during cardiac catheterization 
procedures. Deceleration (time from peak E-wave velocity to zero) and isovolumic relaxation 
time (time from systolic ventricular outflow to mitral valve opening) may be normal or shorter. 
The isovolumic relaxation time, percentage of diastolic time to LV filling, LV compliance, and 
LV wall strain during diastole are then used to quantify diastolic function. The position of the 
pressure-volume curve and the slope of the pressure-volume relationship must be known to 
comprehensively evaluate diastolic function.64,65However, given the numerous factors that may 
alter diastolic function, it is unlikely that any one index will be developed to adequately reflect 
diastolic function. 
 
In most clinical settings, diastolic function is estimated using Doppler echocardiography. With 
this noninvasive procedure, an objective measure of flow velocities from the left atrium to the 
LV across the mitral valve indirectly estimates LV filling pressure and diastolic function. 
Doppler echocardiography evaluation of LV filling correlates well with cardiac catheterization 
findings of LV volume during diastole.65 
 
Doppler echocardiography includes two biphasic components: the E wave, which reflects early 
diastolic filling, and the A wave in late diastole, which reflects atrial contraction. These findings 
are most often expressed as the E/A ratio and are normally greater than 1, indicating both short 
isovolumic relaxation and deceleration time.64,65 Echocardiographic evaluation is advantageous 
clinically because it can rapidly rule out diagnoses such as acute mitral or aortic regurgitation 
and constrictive pericarditis, which are also associated with signs and symptoms of HF and a 
normal ejection fraction. However, patient characteristics (eg, age, gender, and heart rate) and 
physiologic variables (eg, preload, LV relaxation, left atrial pressure, and LV compliance) are 
important obstacles that make interpretation of Doppler echocardiography findings more 
difficult. 
 
Three abnormal diastolic filling patterns that describe the type and severity of diastolic 
dysfunction have been reported in a number of studies. Delayed relaxation occurs with normal 
aging, as well as LV ischemia and hypertrophy. In the delayed relaxation pattern, relaxation of 
the LV progressively slows with an accompanying reduction in the early diastolic pressure 
gradient. An increased compensatory atrial response to LV filling occurs, and as a result the E/A 
ratio reverses to less than 1. Patients in this group are often hypertensive, have LVH, and may 
develop DHF over time. 
 
Pseudonormalization is the second pattern of abnormal LV filling; this refers to the 
“pseudonormal” E/A ratio greater than 1. An increased left atrial pressure to compensate for the 
slowed relaxation time is characteristic of this pattern. An increased left atrial pressure to 
compensate for the slowed relaxation time is characteristic of this pattern. In some patients, use 
of the Valsalva maneuver may result in an inversion of the E/A ratio and facilitate better 
recognition of this abnormal pattern. Patients with this type of pattern typically have structural 
changes and established cardiac disease.64,65 
 
Restrictive filling is the third abnormal LV filling pattern. During diastole, ventricular pressures 
rapidly increase and LV filling is negligible, resulting in an increased E/A ratio, often greater 
than 2, accompanied by a short deceleration time and isovolumic relaxation time. A restrictive 
pattern that is not reversed by HF therapies denotes a poor prognosis. Patients' condition can 
deteriorate rapidly or improve if optimal pharmacologic strategies are introduced.64 
 
Treatment Strategies 
 
Although there is substantial evidence to guide therapy for patients with SHF, few trials have 
been conducted with patients with DHF; therefore, little is known about optimal treatment 
strategies for this population. The management of DHF has two major objectives: to reverse the 
consequences of diastolic dysfunction (eg, venous congestion and exercise intolerance) and to 
eliminate or reduce factors (eg, hypertension) responsible for the diastolic dysfunction.5,8,14,66-
68 Other important goals of therapy include reducing the number of hospitalizations, increasing 
exercise tolerance, and improving overall quality of life (QOL).8 
 
The Heart Failure Society of America69 has published comprehensive guidelines for the 
treatment of HF based on Level A (randomized controlled trials), Level B (cohort case-control 
studies), and Level C (expert opinion) data. Recommendations for DHF are primarily Level C, 
reflecting the lack of clinical trial data for this population. The only Level A data reported are 
from the CHARM-Preserved trial,31 which included 3023 patients in NYHA class II to IV with 
an LVEF greater than 40% who received either candesartan (target dose 32 mg once daily) or a 
matching placebo and were followed for a median of 37 months. Although cardiovascular death 
did not differ in the treatment groups, fewer patients in the candesartan group were hospitalized 
for HF (P = .017). On the basis of these findings, treatment for DHF is recommended primarily 
for those who are symptomatic (NYHA class II–IV) because there is no evidence to indicate that 
treatment of asymptomatic patients with DHF is beneficial, other than controlling for 
hypertension. Because hypertension is the most common modifiable risk factor for the 
development of LVH other than age, aggressively treating blood pressure may be an important 
preventative measure for future development of DHF. Systolic blood pressure should be less than 
140 mm Hg in general and less than 130 mm Hg in persons with diabetes.44 
 
Symptom Management 
 
Initially, patients with DHF often have symptoms related to pulmonary congestion. Pulmonary 
congestion can be decreased by reducing LV volume, maintaining normal sinus rhythm 
(arteriovenous synchrony), and prolonging diastole (thereby decreasing heart rate and increasing 
coronary artery filling time). One of the most common interventions to reduce LV volume is 
reducing intravascular volume, either by diuretics or nonpharmacologic approaches such as fluid 
or sodium restriction. Other interventions to reduce LV volume include decreasing central blood 
volume (by nitrate use) or blocking neurohormonal activation, more specifically blocking 
activation of the renin-angiotensin-aldosterone system (RAAS) system. Treatments aimed at 
blocking activation of the RAAS include the use of RAAS antagonists, such as ACEIs, ARBs, 
and aldosterone antagonists.8,14,66-70 
 
Pharmacologic Treatment of Diastolic Heart Failure 
 
Neurohormonal activation contributes to reduced cardiac output and exertional intolerance in 
patients with DHF.71 Specific therapeutic targets include reducing blood pressure; controlling 
hypertension, ischemia, and tachycardia; and maintaining a sinus rhythm. Beta-adrenergic 
receptor blockers decrease blood pressure and reduce ventricular remodeling by lowering the 
harmful neurohormonal and cytokine cascade. Reducing heart rate is also essential using beta-
blockade to improve diastolic filling time and volume, thereby increasing cardiac output.8,14,66,72 
 
Diuretics in DHF are used to reduce congestion and circulation volume. Diuretic dosages should 
be used judiciously in DHF to avoid hypotension, fatigue, and renal impairment. Hypotension is 
especially important with DHF because small changes in diastolic volume may cause large 
changes in pressure and cardiac output, especially in individuals with a steep diastolic pressure-
volume curve. Long-acting nitrates may also be used to decrease circulation volume and thus 
reduce pulmonary congestion through LV volume reduction.14,71,72 
 
ACEIs or ARBs that inhibit activation of the RAAS have also been used in the treatment of 
DHF. Clinical trials investigating the use of ACEIs or ARBs for treatment of DHF have been 
limited; however, the major predictors of DHF, namely, advanced age, hypertension, LVH, 
diabetes, and coronary heart disease, have shown improvement with ACEI or ARB 
use.72,73 Warner et al74 found that the use of Losartan improved exercise tolerance and QOL in 20 
patients with DHF. These findings were supported by Little and colleagues,75who demonstrated 
that losartan and hydrochlorothiazide blunted hypertensive response to exercise in 40 patients 
with DHF, but only losartan also improved exercise tolerance and QOL. In addition, in the 
CHARM-Added substudy, the addition of candesartan for patients already taking an ACEI (N = 
1276) significantly reduced the mortality and number of hospitalizations in patients with SHF, 
although this has not been comprehensively evaluated in patients with DHF.33 In contrast, other 
studies have shown no clear benefit for ACEIs in patients with DHF.14,80 Nevertheless, current 
evidence suggests that ACEIs are preferable to ARBs based on clinical trial data showing 
reduced mortality, lower hospitalization rates, fewer side effects, and lower 
costs.8,14,66,67 Aldosterone receptor antagonists have also shown positive results in patients with 
SHF, and they are recommended early for patients with SHF after an acute myocardial infarction 
in the absence of hyperkalemia or renal dysfunction.76 Further studies, however, are needed in 
patients with DHF to determine which pharmacologic regimen offers the most benefit. 
 
Positive inotropic agents, such as digoxin, should generally not be used on a long-term basis for 
treatment of patients with DHF. There seems to be little benefit when there is preserved systolic 
function, and these agents may worsen the pathophysiologic mechanisms that cause DHF. 
Caution should be used even in the short-term use of positive inotropes for patients with DHF. 
An ancillary study of 988 patients with a preserved LVEF in the Digitalis Investigation 
Group77,78 found no significant differences from placebo in mortality rates or hospitalization. 
Specifically, the use of digoxin was associated with a trend toward a reduction in hospitalizations 
resulting from worsening HF (hazard ratio, .79; 95% confidence interval, .59–1.04; P = .094) but 
also a trend toward an increase in hospitalizations for unstable angina (hazard ratio, 1.37; 95% 
confidence interval, .99–1.91; P = .061). The potential beneficial effects of digoxin in DHF may 
be related to its favorable effects on neurohormonal activation, although further investigation is 
warranted.77 
 
Nonpharmacologic Management 
 
DHF and aging both lead to a reduced exercise capacity, in part because of the loss of muscle 
mass (sarcopenia) and alterations in skeletal muscle blood flow and metabolism. Exercise 
training can in part reverse the peripheral alteration, improve functional capacity, and improve 
the symptoms associated with DHF and is now recommended by the American Heart 
Association/American College of Cardiology guidelines73,79 and Heart Failure Society of 
America69 in stable patients with NYHA class I to III. However, patients with DHF are at a 
disadvantage because there is currently no Medicare reimbursement for cardiac rehabilitation 
programs for patients with a nonischemic HF cause. In addition, because patients with DHF are 
typically older and female, transportation, cost constraints, and care-taking responsibilities often 
interfere with participation in site-based cardiac rehabilitation programs, making a home-based 
approach a more practical alternative.79-90Several small trials have shown that home-based, low-
intensity (40%) walking is associated with low risk and has been shown to improve physical 
function and QOL in some patients with DHF.67,81 The ongoing Heart Failure—A Controlled 
Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) trial is expected to provide 
greater insight into the effects of exercise in patients with SHF; whether these data can be 
extrapolated to patients with DHF who may also benefit from different modes of exercise 
therapy is an area for further discussion.79 
 
To encourage patients to exercise at home, they should be provided with a basic exercise 
prescription (frequency and duration of exercise) and know how to self-monitor 
symptoms.82 Exercise intensity can be prescribed using Borg's rate of perceived exertion scale 
(Table II,)82 which asks patients to rate their perceived exertion or how hard they feel they are 
exerting themselves physically on a scale from 6 to 20. Initially, patients are instructed to keep 
their exertion level at 11 or 12 initially, which corresponds to light exertion. Patients should be 
instructed to progress slowly and to closely monitor their heart rate and dyspnea level. A good 
rule of thumb is to instruct the patient to exercise at a level that enables them to walk and talk 
simultaneously. 
 
Table II. Borg's rate of perceived exertion scale 
Exertion RPE 
No exertion at all 6 
Extremely light 7  
8 
Very light 9  
10 
Light 11  
12 
Somewhat hard 13  
14 
Hard (heavy) 15  
16 
Very hard 17  
18 
Extremely hard 19 
Maximal exertion 20 
RPE, Rate of perceived exertion. 
With permission from: Borg G. Borg's perceived exertion and pain scales. Human Kinetics; 
1998. 
 
Heart rate monitors and simple exercise logs can facilitate exercise self-efficacy83 by enabling 
the patient to track their weekly progress. Improved exercise self-efficacy has been shown to 
positively influence exercise adherence and maintenance in patients with HF and women with 
DHF. Other essential equipment for a home-based exercise program includes blood pressure 
monitors and weight scales. Before beginning an exercise program, patients should be instructed 
to weigh daily because rapid weight gain may occur in some patients and require medication 
adjustments. Patients should also be told to monitor their heart rate carefully for a rapid increase, 
blood pressure elevation, and pulmonary congestion, which may exacerbate their symptoms and 
lead to greater diastolic dysfunction.16,20 
 
Treatment of the underlying factors contributing to DHF, such as long-standing hypertension, 
remains the key to preventing disease progression. Trends in blood pressure over time, how self-
monitoring of blood pressure is performed by the patient, and the response to blood pressure 
management are clinically important information that should be tracked in an organized fashion 
by clinicians. Whether adherence to hypertensive medication regimen is problematic because of 
socioeconomic reasons, cognitive issues, or other factors should be evaluated during routine 
clinic or office visits.8 
 
The patient and family members should be educated and understand the rationale for HF self-
management care, including self-monitoring of daily blood pressure and weight, dietary sodium 
restrictions, physical activity level, and medication adherence. Patients should have quick access 
to primary health care providers in the event of increasing blood pressure or weight gains. 
Patients provided with blood pressure, weight, and symptom telemonitoring84,85 to document and 
track their daily responses and self-management decisions have been shown to reduce the 
number of hospital readmissions and costs associated with HF treatment. 
 
Nonadherence to dietary sodium restrictions results in unnecessary hospitalizations and requires 
the nurse to reinforce sodium dietary restrictions during clinic visits or telephone follow-up. For 
example, determining whether patients or family members can read labels for sodium content or 
interpret various labels for portion size should be an essential component of self-management 
education.86 Because patients with DHF are typically older, female, and widowed, and live alone, 
they may lack adequate social support or socioeconomic resources to purchase medications 
consistently, shop for appropriate low-sodium food, or participate in physical or social activities, 
all of which may place them at higher risk for poor clinical outcomes. During routine visits, 
evaluation of subtle changes in self-care abilities, such as loss of transportation, may indicate a 
need for additional resources to avoid illness exacerbations and hospital readmissions.87,88 
 
Patients with DHF may also be at higher risk for depression because of age-related transitions, 
such as loss of spouse, relocation or change in living environment, and limitations in the ability 
to conduct physical activities of daily living.81,89-91 The strong evidence supporting the 
relationship between lack of social support and depressive symptoms with negative cardiac 
outcomes and hospital readmission and death indicates a need for ongoing psychosocial 
evaluation.91-93 Simple diagnostic tests that may be used in the clinical setting include the Brief 
Symptom Inventory94 or simply asking the patient about his or her mood. 
 
Multidisciplinary Management 
 
The complex syndrome of DHF is often complicated by multiple comorbidities, advancing age, 
lack of resources, sensory deficits, mobility limitations, depression, nutritional concerns, social 
isolation, and end-of-life decisions. These factors contribute to poor outcomes, nonadherence to 
medical regimens, increased hospitalizations, and institutionalization. The complexity of issues 
surrounding many patients with DHF requires a multidisciplinary approach to ensure these issues 
are addressed to improve clinical outcomes. Although the findings are mixed, several recent 
studies have documented the effectiveness of HF disease-management programs in reducing the 
number of hospitalizations and medical costs, and improving QOL in older patients, who more 
commonly have DHF.95,96 
 
Conclusions 
 
Although there are few clinical trials to provide strong support for treatment options in DHF, the 
number of studies is increasing and evidence has steadily grown during the past decade, 
providing enthusiasm that future therapies will emerge. The most effective management is the 
prevention of DHF, which includes strategies aimed at aggressively treating the established risk 
factors, such as hypertension, diabetes, and obesity. In the meantime, nurses have an important 
role to play in educating patients about a low-sodium diet, lifestyle modifications, and a 
medication regimen to reduce symptom severity, exacerbations, and hospitalizations. Moreover, 
the role of palliative care in reducing symptom severity and enhancing QOL in patients who are 
older and have advanced DHF is an area that has had little investigation. Finally, to address the 
increasing burden of DHF, research must be refocused to include older adults and especially 
women, whose underlying disease pathology is more often diastolic dysfunction. 
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